AnaptysBio マネジメント

マネジメント基準チェック /34

AnaptysBioの CEO はDan Fagaで、 Mar2022年に任命され、の在任期間は 2.67年です。の年間総報酬は$ 7.46Mで、 8.6%給与と91.4%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.32%を直接所有しており、その価値は€ 9.24M 。経営陣と取締役会の平均在任期間はそれぞれ2.7年と3.7年です。

主要情報

Dan Faga

最高経営責任者

US$7.5m

報酬総額

CEO給与比率	8.6%
CEO在任期間	2.7yrs
CEOの所有権	1.3%
経営陣の平均在職期間	2.7yrs
取締役会の平均在任期間	3.7yrs

経営陣の近況

Recent updates

CEO報酬分析

AnaptysBio の収益と比較して、Dan Faga の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$166m
Jun 30 2024	n/a	n/a	-US$170m
Mar 31 2024	n/a	n/a	-US$163m
Dec 31 2023	US$7m	US$641k	-US$164m
Sep 30 2023	n/a	n/a	-US$148m
Jun 30 2023	n/a	n/a	-US$144m
Mar 31 2023	n/a	n/a	-US$137m
Dec 31 2022	US$25m	US$474k	-US$129m
Sep 30 2022	n/a	n/a	-US$135m
Jun 30 2022	n/a	n/a	-US$108m
Mar 31 2022	n/a	n/a	-US$76m
Dec 31 2021	US$310k	n/a	-US$58m

報酬と市場: Danの総報酬 ($USD 7.46M ) は、 German市場 ($USD 1.44M ) の同規模の企業の平均を上回っています。

報酬と収益: Danの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Dan Faga (44 yo)

2.7yrs

在職期間

US$7,461,920

報酬

Mr. Daniel R. Faga, also known as Dan, is Director of Affini-T Therapeutics, Inc. from April 2022. He serves as Director at AnaptysBio, Inc. since November 2021 and is its President and Chief Executive Off...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Daniel Faga	President	2.7yrs	US$7.46m	1.32% € 9.2m
Eric Loumeau	Chief Legal Officer	6.3yrs	US$2.26m	0.011% € 74.5k
Paul Lizzul	Chief Medical Officer	4.3yrs	US$2.44m	0.051% € 354.2k
Dennis Mulroy	Chief Financial Officer	4.3yrs	US$1.81m	0.016% € 109.1k
Beth Mueller	Senior Vice President of Human Resources	5.1yrs	データなし	データなし
Martin Dahl	Senior Vice President of Research	2.8yrs	データなし	データなし
Benjamin Stone	Chief Business Officer	less than a year	データなし	データなし
Douglas Rich	Senior Vice President of CMC	1.8yrs	データなし	データなし
Monique Da Silva	Senior Vice President of Corporate Affairs	less than a year	データなし	データなし
Priya Raina	Senior Vice President of Clinical Operations	less than a year	データなし	データなし
Min Bao	Senior Vice President of Clinical Development	less than a year	データなし	データなし

2.7yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: AN6の経営陣は経験豊富であると考えられます ( 2.7年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Daniel Faga	President	3yrs	US$7.46m	1.32% € 9.2m
John Orwin	Independent Chairman of the Board	1.2yrs	US$338.08k	0.011% € 76.7k
Hollings Renton	Lead Independent Director	9.4yrs	US$342.38k	0.0064% € 44.9k
John Schmid	Independent Director	9.4yrs	US$335.38k	0.013% € 89.7k
Dennis Fenton	Independent Director	6.7yrs	US$331.88k	0.0064% € 44.9k
Magda Marquet	Independent Director	3.8yrs	US$318.38k	0.013% € 89.7k
Oleg Nodelman	Independent Director	3.6yrs	データなし	データなし
J. Ware	Independent Director	7.3yrs	US$338.38k	0.025% € 172.5k
Rita Jain	Independent Director	1.6yrs	US$495.60k	0.015% € 104.3k
Dolca Thomas	Member of Scientific Advisory Board	1.8yrs	データなし	データなし
Luisa Salter-Cid	Member of Scientific Advisory Board	no data	データなし	データなし
John Monroe	Member of Scientific Advisory Board	no data	データなし	データなし

3.7yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: AN6の取締役会は経験豊富であると考えられます ( 3.7年の平均在任期間)。

AnaptysBio マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold €3.1m worth of stock

AnaptysBio, Inc. Announces Board Changes

High number of new directors

High number of new directors

AnaptysBio, Inc., Annual General Meeting, Jun 23, 2022

Recent updates

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2024 earnings released: US$1.14 loss per share (vs US$1.41 loss in 3Q 2023)

AnaptysBio, Inc. has filed a Follow-on Equity Offering in the amount of $100.393177 million.

Second quarter 2024 earnings released: US$1.71 loss per share (vs US$1.50 loss in 2Q 2023)

New minor risk - Shareholder dilution

Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

First quarter 2024 earnings released: US$1.64 loss per share (vs US$1.58 loss in 1Q 2023)

AnaptysBio, Inc., Annual General Meeting, Jun 12, 2024

President recently sold €3.1m worth of stock

New minor risk - Share price stability

New minor risk - Profitability

No longer forecast to breakeven

No longer forecast to breakeven

No longer forecast to breakeven

New minor risk - Profitability

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$1.18 loss in 3Q 2022)

AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

AnaptysBio, Inc. Announces Board Changes

High number of new directors

Second quarter 2023 earnings released: US$1.50 loss per share (vs US$1.15 loss in 2Q 2022)

AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

New minor risk - Share price stability

Forecast to breakeven in 2025

First quarter 2023 earnings released: US$1.58 loss per share (vs US$1.31 loss in 1Q 2022)

Forecast to breakeven in 2025

Full year 2022 earnings released: US$4.57 loss per share (vs US$2.11 loss in FY 2021)

AnaptysBio, Inc. (NasdaqGS:ANAB) announces an Equity Buyback for $50 million worth of its shares.

AnaptysBio Announces Portfolio

Anaptysbio- and GSK-Partnered Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Meets Primary Endpoint in Phase 3 Ruby Trial in Primary Advanced or Recurrent Endometrial Cancer

Third quarter 2022 earnings released: US$1.18 loss per share (vs US$0.24 loss in 3Q 2021)

Anaptysbio and Gsk-Partnered Immuno-Oncology Agents Jemperli (Dostarlimab-Gxly) and Cobolimab Show Positive Progress in Two Separate Non-Small Cell Lung Cancer Trials

AnaptysBio, Inc. Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa

Second quarter 2022 earnings released: US$1.15 loss per share (vs US$0.016 loss in 2Q 2021)

High number of new directors

First quarter 2022 earnings released: US$1.31 loss per share (vs US$0.66 loss in 1Q 2021)

AnaptysBio, Inc., Annual General Meeting, Jun 23, 2022

Forecast to breakeven in 2024

AnaptysBio, Inc. Announces FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.30 loss in 1Q 2020)

AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pustulosis (PPP) Did Not Meet Primary Endpoint

Full year 2020 earnings released: US$0.73 loss per share (vs US$3.60 loss in FY 2019)

Revenue beats expectations

New 90-day high: €27.92

AnaptysBio, Inc. Announces Board Changes

AnaptysBio, Inc. Enters into Certain Termination of Sublease with Trex Enterprises Corporation

Revenue in line with expectations

New 90-day high: €25.43

Anaptysbio, Inc. Enters into an Amendment to Its Collaboration and Exclusive License Agreement with Tesaro, Inc., and Tesaro Development, Ltd

New 90-day high: €20.65

AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)

New 90-day low - €12.07

New 90-day low - €14.11

First half earnings released

AnaptysBio, Inc.(NasdaqGS:ANAB) dropped from Russell 3000 Growth Index

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34